NeoGenomics, Inc. Reports Revenue of $15.6 Million, Adjusted EBITDA of $1.8 Million and Earnings per share of $0.01 for the Second Quarter 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

FT. MYERS, Fla., July 31, 2013 -- /PRNewswire/ -- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services today reported its results for the second quarter of 2013.

Second Quarter 2013 Highlights:

Earnings per share of $0.01 per share on net income of $273k

Adjusted EBITDA(1) of $1.8 million

Hey, check out all the research scientist jobs. Post your resume today!